Animal experiments have shown that enhanced SUMOylation of FXR strongly impairs FXR signaling and that SUMOylation inhibitors can enhance the efficacy of FXR agonists to delay the progression of liver fibrosis.254. This evidence concerns the gene NR1H4 and Hepatic fibrosis.